Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of
paliperidone ER (extended-release), an antipsychotic, treatment in patients with
schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but
who are not satisfied with their treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.